Vera Loizzi1, Ettore Cicinelli2, Vittoria Del Vecchio3, Francesca Arezzo4, Xheni Deromemaj5, Anila Kardhashi6, Angelo Paradiso7, Francesco Legge8, Maria Iole Natalicchio9, Leonardo Resta10, Nicoletta Resta11, Daria Carmela Loconte12, Gennaro Cormio13. 1. Obstetrics and Gynecology Unit, DIM Department, University of Bari, Italy. vera.loizzi@uniba.it. 2. Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy . ettore.cicinelli@uniba.it. 3. Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy . vittoria.delvecchiomd@gmail.com. 4. a:1:{s:5:"en_US";s:116:"Department of Biomedical Sciences and Human Oncology, University of Bari, Italy Piazza Giulio Cesare 11, Bari Italy ";}. francescaarezzo@libero.it. 5. Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy . x.deromemaj@yahoo.it. 6. Gynecology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. anila.kardhashi@oncologico.bari.it. 7. Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. angelo.paradiso@oncologico.bari.it. 8. Gynecologic Oncology Unit, General Regional Hospital "F. Miulli" of Acquaviva delle Fonti, Italy. francescolegge@libero.it. 9. Molecular Oncology and Pharmacogenomics laboratory, University of Foggia, Italy. iole.nat@tiscali.it. 10. Department of Pathology, University of Bari, Italy.. leonardo.resta@uniba.it. 11. Medical Genetics Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. nicoletta.resta@uniba.it. 12. Medical Genetics Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. dariacarmela.loconte@uniba.it. 13. Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy . gennaro.cormio@uniba.it.
Abstract
BACKGROUND AND AIM OF THE WORK: BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. METHODS: Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, median age was 51 years) and BRCA 2 mutation (aged between 36-70 years, median age was 53 years). Fifty-eight patients had previous history of breast cancer. RESULTS: Between the 100 patients, 82 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7 (7 %) underwent laparoscopic RRSO and contextual hysterectomy, 1 woman (1 %) underwent RRSO through a laparotomic approach and 10 women (10 %) laparotomic RRSO and hysterectomy. During 5 (5 %) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 3 patients (3 %). Two patients (2 %) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and three patients (3 %) occult cancer. CONCLUSIONS: RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.
BACKGROUND AND AIM OF THE WORK: BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. METHODS: Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, median age was 51 years) and BRCA 2 mutation (aged between 36-70 years, median age was 53 years). Fifty-eight patients had previous history of breast cancer. RESULTS: Between the 100 patients, 82 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7 (7 %) underwent laparoscopic RRSO and contextual hysterectomy, 1 woman (1 %) underwent RRSO through a laparotomic approach and 10 women (10 %) laparotomic RRSO and hysterectomy. During 5 (5 %) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 3 patients (3 %). Two patients (2 %) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and three patients (3 %) occult cancer. CONCLUSIONS: RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.
Authors: Adrianne Mallen; T Rinda Soong; Mary K Townsend; Robert M Wenham; Christopher P Crum; Shelley S Tworoger Journal: Gynecol Oncol Date: 2018-08-04 Impact factor: 5.482
Authors: L Webber; M Davies; R Anderson; J Bartlett; D Braat; B Cartwright; R Cifkova; S de Muinck Keizer-Schrama; E Hogervorst; F Janse; L Liao; V Vlaisavljevic; C Zillikens; N Vermeulen Journal: Hum Reprod Date: 2016-03-22 Impact factor: 6.918
Authors: Joanne Kotsopoulos; Jacek Gronwald; Beth Y Karlan; Tomasz Huzarski; Nadine Tung; Pal Moller; Susan Armel; Henry T Lynch; Leigha Senter; Andrea Eisen; Christian F Singer; William D Foulkes; Michelle R Jacobson; Ping Sun; Jan Lubinski; Steven A Narod Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777